Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Cash from Operations (2020 - 2023)

Historic Cash from Operations for Terns Pharmaceuticals (TERN) over the last 4 years, with Q4 2023 value amounting to -$19.3 million.

  • Terns Pharmaceuticals' Cash from Operations fell 7229.51% to -$19.3 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$67.4 million, marking a year-over-year decrease of 3722.54%. This contributed to the annual value of -$70.0 million for FY2024, which is 389.67% down from last year.
  • Latest data reveals that Terns Pharmaceuticals reported Cash from Operations of -$19.3 million as of Q4 2023, which was down 7229.51% from -$20.7 million recorded in Q3 2023.
  • Terns Pharmaceuticals' Cash from Operations' 5-year high stood at -$6.3 million during Q3 2020, with a 5-year trough of -$20.7 million in Q3 2023.
  • Moreover, its 4-year median value for Cash from Operations was -$11.2 million (2022), whereas its average is -$11.8 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first crashed by 9645.94% in 2021, then skyrocketed by 709.7% in 2022.
  • Terns Pharmaceuticals' Cash from Operations (Quarter) stood at -$7.4 million in 2020, then crashed by 44.43% to -$10.7 million in 2021, then decreased by 5.08% to -$11.2 million in 2022, then tumbled by 72.3% to -$19.3 million in 2023.
  • Its Cash from Operations stands at -$19.3 million for Q4 2023, versus -$20.7 million for Q3 2023 and -$13.0 million for Q2 2023.